Tianjin Pharmaceutical Da Ren Tang Group Dividends and Buybacks
Dividend criteria checks 3/6
Tianjin Pharmaceutical Da Ren Tang Group is a dividend paying company with a current yield of 4.02%.
Key information
4.0%
Dividend yield
0.1%
Buyback Yield
Total Shareholder Yield | 4.1% |
Future Dividend Yield | 4.0% |
Dividend Growth | 16.5% |
Next dividend pay date | n/a |
Ex dividend date | n/a |
Dividend per share | CN¥1.280 |
Payout ratio | 106% |
Recent dividend and buyback updates
Recent updates
Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Could Easily Take On More Debt
Dec 18Are Investors Undervaluing Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329) By 48%?
Oct 27Why Investors Shouldn't Be Surprised By Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SHSE:600329) 36% Share Price Surge
Oct 08Some Shareholders Feeling Restless Over Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SHSE:600329) P/E Ratio
Jul 26Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet
Jul 05Fewer Investors Than Expected Jumping On Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329)
Apr 18Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet
Mar 18Stability and Growth of Payments
Fetching dividends data
Stable Dividend: 600329's dividend payments have been volatile in the past 10 years.
Growing Dividend: 600329's dividend payments have increased over the past 10 years.
Dividend Yield vs Market
Tianjin Pharmaceutical Da Ren Tang Group Dividend Yield vs Market |
---|
Segment | Dividend Yield |
---|---|
Company (600329) | 4.0% |
Market Bottom 25% (CN) | 0.5% |
Market Top 25% (CN) | 2.1% |
Industry Average (Pharmaceuticals) | 1.8% |
Analyst forecast (600329) (up to 3 years) | 4.0% |
Notable Dividend: 600329's dividend (4.02%) is higher than the bottom 25% of dividend payers in the CN market (0.54%).
High Dividend: 600329's dividend (4.02%) is in the top 25% of dividend payers in the CN market (2.09%)
Earnings Payout to Shareholders
Earnings Coverage: With its high payout ratio (105.8%), 600329's dividend payments are not well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its high cash payout ratio (95%), 600329's dividend payments are not well covered by cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/19 08:31 |
End of Day Share Price | 2024/12/19 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited is covered by 10 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Yalei Yan | Bohai Securities Co., Ltd. |
Chengzhi Chen | CGS International |
Shanshan Li | China Merchants Securities Co. Ltd. |